Compare Hyatt Hotels Corporation (H) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Summit Therapeutics Inc — how do they compare? Hyatt Hotels Corporation trades at $161.82 (market cap $15.02B), while Summit Therapeutics Inc trades at $17.44 (market cap $13.71B). The key difference: Hyatt Hotels Corporation and Summit Therapeutics Inc are close in size by market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and Summit Therapeutics Inc for 16 Days on average.
| H | SMMT | |
|---|---|---|
Market Cap | $15.02B | $13.71B |
Volume | 842,340 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $26.38 |
52-Week Low | $135.42 | $12.43 |
Typical Hold Time | 148 Days | 16 Days |
Enterprise Value | $18.93B | $13.04B |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $161.75, up 2.93% with recent earnings beats driving momentum. The stock shows neutral technical signals with mixed moving averages and oscillators. Fundamentally, revenue grew to $7.1B in 2025 but net income turned negative at -$52M, while valuation metrics remain elevated with P/E at 196.83. Recent developments include strategic partnerships with Delta Air Lines and expansion of the Essentials portfolio.
Outlook remains cautiously optimistic with analyst consensus target of $197.77 (22% upside) but high valuation and negative cash flow trends pose risks. The company's growth initiatives and brand expansion provide opportunities, though investors should monitor debt levels and profitability recovery.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
